Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC202 with or without ASK120067 in advanced solid tumors
NCT05306132Phase 1Recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of askc202 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
askc202
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05306132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306132.